Our Services
Medical Information
Helpful Resources
Published on: 9/15/2026
Tingling or "pins and needles" is not a typical listed side effect of Wegovy (semaglutide), so it is worth taking seriously rather than dismissing. Possible explanations include low vitamin B12, B1 (thiamine), or B6 levels caused by reduced food intake and rapid weight loss, dehydration and electrolyte shifts from nausea, vomiting, or diarrhea, rapid blood sugar changes in people with diabetes (treatment-induced neuropathy), or an unrelated condition such as pinched nerves, thyroid disease, or pre-existing neuropathy being unmasked. True nerve damage is uncommon, but persistent, worsening, or symmetrical numbness in the hands and feet, along with weakness, burning pain, or balance problems, points toward a nerve or nutrient issue that needs testing rather than watchful waiting. Certain features, including facial numbness, sudden one-sided symptoms, or trouble speaking or walking, are red flags for an emergency instead of a medication side effect. Several factors determine which cause is most likely for you, including your dose, how long you have been on it, your eating patterns, and your other health conditions, so see below to understand more before assuming this is simply the drug.
Because tingling can stem from something easily corrected, like a B12 deficiency, or something that needs prompt evaluation, guessing is the riskiest option. A free, instant, online symptom check lets you enter your specific pattern of tingling, timing, and other symptoms in a few minutes and receive possible causes matched to your situation. It also helps you decide whether to request bloodwork, contact your prescriber about your dose, or seek urgent care, and it gives you clearer language to describe your symptoms so nothing important gets missed at your appointment.
If you’ve started on Wegovy (semaglutide) and noticed tingling, prickling, or “pins and needles,” you’re not alone in asking, “why does Wegovy cause dysaesthesia?” While nerve damage and vitamin deficiencies are possible explanations, neither is common. Below, we’ll explore what dysaesthesia means, potential causes related to Wegovy, when to worry, and what steps you can take.
Strictly speaking, Wegovy does not directly injure nerves. Instead, several indirect factors tied to its mechanism and effects can lead to dysaesthesia:
True nerve damage (neuropathy) means structural injury to nerve fibers. On Wegovy, this is rare. Consider nerve damage if you experience:
If you tick any of these boxes, nerve conduction studies or an EMG (electromyography) by a neurologist can clarify whether actual nerve fibers are damaged.
Wegovy’s appetite suppression may inadvertently reduce the intake of nutrients essential for nerve function. Deficiencies to watch for include:
Although most cases of tingling on Wegovy are mild and reversible, contact a healthcare professional right away if you experience:
These could signal serious conditions like Guillain-Barré syndrome or severe electrolyte imbalance.
Tingling or dysaesthesia on Wegovy is more often a temporary nuisance than true nerve damage. However, it’s essential to rule out vitamin deficiencies, rapid blood sugar shifts, and rare but serious neurologic conditions. By tracking your symptoms, getting the right blood tests, and maintaining open communication with your healthcare team, you can enjoy the benefits of Wegovy while keeping nerve-related side effects in check.
If you’re concerned about persistent or severe tingling, talk to your doctor. For a head start on pinpointing possible causes, you might try a free, online symptom check, using the doctor approved Ubie Symptom Checker. And remember, anything that feels life-threatening or seriously alarming warrants immediate medical attention—don’t hesitate to seek professional help.
(References)
* Goldney J, Sargeant JA, Davies MJ. Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. Diabetologia. 2023 Oct;66(10):1832-1845. doi: 10.1007/s00125-023-05988-3. Epub 2023 Aug 19. PMID: 37597048; PMCID: PMC10474214.
* Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW Jr, Cestari D, Mallery R, Abbasi B, Bouffard M, Chwalisz BK, Estrela T, Rizzo JF 3rd. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024 Aug 1;142(8):732-739. doi: 10.1001/jamaophthalmol.2024.2296. PMID: 38958939; PMCID: PMC11223051.
* Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024 Aug 20;332(7):571-584. doi: 10.1001/jama.2024.10816. PMID: 39037780.
* Katz BJ, Lee MS, Lincoff NS, Abel AS, Chowdhary S, Ellis BD, Najafi A, Nguyen J, Seay MD, Warner JEA. Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide. JAMA Ophthalmol. 2025 Mar 1;143(3):215-220. doi: 10.1001/jamaophthalmol.2024.6058. PMID: 39883468; PMCID: PMC11783245.
* Pillarisetti L, Agrawal DK. Semaglutide: Double-edged Sword with Risks and Benefits. Arch Intern Med Res. 2025;8(1):1-13. doi: 10.26502/aimr.0189. Epub 2025 Jan 10. PMID: 39902055; PMCID: PMC11790292.
* Cai CX, Hribar M, Baxter S, Goetz K, Swaminathan SS, Flowers A, Brown EN, Toy B, Xu B, Chen J, Chen A, Wang S, Lee C, Leng T, Ehrlich JR, Barkmeier A, Armbrust KR, Boland MV, Dorr D, Boyce D, Alshammari T, Swerdel J, Suchard MA, Schuemie M, Bu F, Sena AG, Hripcsak G, Nishimura A, Nagy P, Falconer T, DuVall SL, Matheny M, Viernes B, O'Brien W, Zhang L, Martin B, Westlund E, Mathioudakis N, Fan R, Wilcox A, Lai A, Stocking JC, Takkouche S, Lee LH, Xie Y, Humes I, McCoy DB, Adibuzzaman M, Areaux RG Jr, Rojas-Carabali W, Brash J, Lee DA, Weiskopf NG, Mawn L, Agrawal R, Morgan-Cooper H, Desai P, Ryan PB. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol. 2025 Apr 1;143(4):304-314. doi: 10.1001/jamaophthalmol.2024.6555. PMID: 39976940; PMCID: PMC11843465.
* Amini A, Hamann S, Larsen M. Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association. Acta Ophthalmol. 2025 Sep;103(6):615-621. doi: 10.1111/aos.17473. Epub 2025 Mar 8. PMID: 40055951; PMCID: PMC12340176.
* Literature Commentary. J Neuroophthalmol. 2024 Dec 1;44(4):587-592. doi: 10.1097/WNO.0000000000002285. PMID: 40418702.
* Natividade GR, Spiazzi BF, Baumgarten MW, Bassotto C, Pereira AA, Fraga BL, Scalco BG, Mattes NR, Lavinsky D, Kramer CK, Gerchman F. Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis. JAMA Ophthalmol. 2025 Sep 1;143(9):759-768. doi: 10.1001/jamaophthalmol.2025.2489. PMID: 40810985; PMCID: PMC12355393.
* Urbina J, Salinas-Ruiz LE, Valenciano C, Clapp B. Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review. Clin Obes. 2026 Feb;16(1):e70070. doi: 10.1111/cob.70070. PMID: 41549912.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.